Table 1.
Characteristicsa | CD163+ TAMs ≤115 (n = 105) | CD163+ TAMs > 115 (n = 104) | P valueb |
---|---|---|---|
Age (years) | 0.607 | ||
≤ 60 | 42 (40.0%) | 38 (36.5%) | |
> 60 | 63 (60.0%) | 66 (63.5%) | |
Sex | 0.216 | ||
Male | 62 (59.0%) | 70 (67.3%) | |
Female | 43 (41.0%) | 34 (32.7%) | |
Location | 0.427 | ||
Rectum | 75 (71.4%) | 69 (66.3%) | |
Colon | 30 (28.6%) | 35 (33.7%) | |
TNM stage | 0.599 | ||
I | 71 (67.6%) | 68 (65.4%) | |
II | 27 (25.7%) | 25 (24.0%) | |
III | 7 (6.7%) | 11 (10.6%) | |
Differentiation | 0.081 | ||
Poorly | 0 (0.0%) | 3 (2.9%) | |
Moderately | 103 (98.1%) | 101 (97.1%) | |
Well | 2 (1.9%) | 0 (0.0%) | |
Examined lymph nodes | 0.020 | ||
≤ 12 | 18 (17.1%) | 7 (6.7%) | |
> 12 | 87 (82.9%) | 97 (93.3%) | |
CEA | 0.721 | ||
< 5 | 79 (75.2%) | 76 (73.1%) | |
≥ 5 | 26 (24.8%) | 28 (26.9%) | |
CA199 | 0.300 | ||
< 37 | 102 (97.1%) | 98 (94.2%) | |
≥ 37 | 3 (2.9%) | 6 (5.8%) |
TAMs, tumor-associated macrophages; TNM, tumor node metastasis; CEA, carcinoembryonic antigen; CA, carbohydrate antigen
an (%)
bChi-square test